Biogen Shares Rise as J.P. Morgan Raises Rating to Overweight

what happened

Biogen shares advanced 3.7% to $234.06 on Monday after J.P. Morgan moved its rating from Neutral to Overweight. Analyst Chris Schott raised the price target to $300 from $210. Dow Jones Market Data indicated that, if the advance holds, the stock would finish at its strongest level since July 2024.

Barron's reported that the upgrade reflects several clinical milestones expected next year. One is felzartamab, a monoclonal antibody obtained through Biogen's $1.8 billion purchase of Human Immunology Biosciences in 2024. In a Phase 2 study of 22 patients with antibody-mediated rejection of transplanted kidneys, biopsy resolution occurred in more than 80% of participants receiving the drug, compared with 20% on placebo. Late-stage results are expected in the first half of next year.

Schott said a potential FDA approval could support rapid adoption because effective AMR treatments are scarce, patients can be identified through a relatively simple process, and Biogen gained an experienced sales organization through its acquisition of Apellis. He estimates that felzartamab could generate $2 billion annually from kidney-transplant rejection alone, with a potentially larger opportunity in other indications. Biogen is also known for Leqembi, its Alzheimer's treatment developed with Eisai, which has posted gradual growth since its 2023 launch and is expected by analysts to produce larger revenue in coming quarters.

The company plans to report fourth-quarter data from two Phase 3 trials of litifilimab in systemic lupus erythematosus, or SLE. The disease is difficult to target because symptoms differ widely and earlier industry trials have delivered inconsistent outcomes. Schott said investors broadly recognize the risk, while several higher-conviction pipeline events are due shortly afterward. Biogen shares are up 33% this year, versus a 19% gain for the iShares Biotechnology ETF.

why it matters

The stock is being valued against both near-term SLE trial uncertainty and the longer-term commercial potential of Biogen's pipeline, making clinical readouts important for market expectations.

instruments